Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Accumulated Expenses (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Accumulated Expenses for 11 consecutive years, with $9.1 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 35.85% to $9.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.1 million through Dec 2025, down 35.85% year-over-year, with the annual reading at $9.1 million for FY2025, 35.85% down from the prior year.
  • Accumulated Expenses hit $9.1 million in Q4 2025 for Voyager Therapeutics, down from $15.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $15.0 million in Q3 2025 to a low of $2.8 million in Q2 2022.
  • Historically, Accumulated Expenses has averaged $8.7 million across 5 years, with a median of $8.4 million in 2022.
  • Biggest five-year swings in Accumulated Expenses: tumbled 74.45% in 2022 and later surged 175.34% in 2024.
  • Year by year, Accumulated Expenses stood at $5.0 million in 2021, then soared by 55.64% to $7.8 million in 2022, then fell by 15.38% to $6.6 million in 2023, then soared by 114.26% to $14.2 million in 2024, then plummeted by 35.85% to $9.1 million in 2025.
  • Business Quant data shows Accumulated Expenses for VYGR at $9.1 million in Q4 2025, $15.0 million in Q3 2025, and $12.0 million in Q2 2025.